GnRH replacement rescues cognition in Down syndrome.
Maria Manfredi-Lozano, Valerie Leysen, Michela Adamo...
https://pubmed.ncbi.nlm.nih.gov/36048943/Actively Recruiting
Led by Nelly Pitteloud · Updated on 2024-02-12
56
Participants Needed
1
Research Sites
N/A
Total Duration
Down syndrome DS is the most common chromosomal disorder, with many adults living to age 65. Early Alzheimers disease AD is the leading cause of death in this group. Individuals with DS show AD-related brain changes by age 30 and develop clinical symptoms in their late 40s. They also experience problems with their sense of smell. Currently, no treatments address these cognitive or olfactory difficulties in DS. Researchers are studying a treatment using pulsatile gonadotropin-releasing hormone GnRH, a natural hormone involved in reproduction and brain functions. This study compares pulsatile GnRH therapy delivered through a subcutaneous pump with a placebo pump over 24 weeks. The treatment is given to people aged 16 to 50 with DS to assess effects on cognition and smell. Participants will undergo cognitive and behavioral assessments, blood tests for metabolic measures, and brain imaging. Researchers will measure changes in cognition from baseline to the end of treatment at week 24. Secondary tests include memory, language, and quality of life evaluations. Safety and health markers will also be monitored. The study includes random assignment to treatment or placebo and uses triple masking to ensure unbiased results.
CONDITIONS
GnRH Therapy on Cognition in Down Syndrome
P
Pulse-UP study
T
Tommaso Todisco, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nelly Pitteloud
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 weeks
Participants receive pulsatile GnRH or placebo therapy administered by a subcutaneous pump to evaluate effects on cognition and other health measures.
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maria Manfredi-Lozano, Valerie Leysen, Michela Adamo...
https://pubmed.ncbi.nlm.nih.gov/36048943/Nelly Pitteloud
Lead Sponsor